An example of this comes from the analysis of circulating tumor DNA in the blood of colorectal cancer (CRC) patients with primary or acquired resistance to epidermal growth factor receptor (EGFR) blockade [5]. This evidence concerns the gene EGFR and colorectal carcinoma.